P21-Activated Kinase Inhibitors

Enzymes

Volumn 34, Issue , 2013, Pages 157-180

  Rudolph, Joachim ^a   Crawford, James J ^a   Hoeflich, Klaus P ^a   Chernoff, Jonathan ^b  

^a GENENTECH INC   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Allosteric kinase inhibitors; ATP competitive kinase inhibitors; Genomic amplification; Kinase selectivity; Ligand efficiency; Oncology; Overexpression; P21 activated kinases

Indexed keywords

P21 ACTIVATED KINASE; PROTEIN KINASE INHIBITOR;

ALLOSTERIC KINASE INHIBITORS; ANIMAL; ARTICLE; ATP-COMPETITIVE KINASE INHIBITORS; DRUG ANTAGONISM; DRUG EFFECT; GENOMIC AMPLIFICATION; HUMAN; KINASE SELECTIVITY; LIGAND EFFICIENCY; ONCOLOGY; OVEREXPRESSION; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALLOSTERIC KINASE INHIBITORS; ATP-COMPETITIVE KINASE INHIBITORS; GENOMIC AMPLIFICATION; KINASE SELECTIVITY; LIGAND EFFICIENCY; ONCOLOGY; OVEREXPRESSION; P21-ACTIVATED KINASES;

ANIMALS; HUMANS; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84887258099     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420146-0.00007-X     Document Type: Chapter

References (75)

1. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7(4):295-308.
2. Wang W., Fang G., Rudolph J. Ras inhibition via direct Ras binding-is there a path forward?. Bioorg. Med. Chem. Lett. 2012, 22(18):5766-5776.
3. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28(6):1075-1083.
4. Pratilas C.A., Solit D.B. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin. Cancer Res. 2010, 16(13):3329-3334.
5. Bai Y., et al. Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development. Cancer Res. 2004, 64(24):8808-8810.
6. González-García A., et al. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 2005, 7(3):219-226.
7. Rathinam R., Berrier A., Alahari S.K. Role of Rho GTPases and their regulators in cancer progression. Front. Biosci. 2011, 16:2561-2571.
8. Stengel K., Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell. Signal. 2011, 23(9):1415-1423.
9. Qiu R.G., et al. An essential role for Rac in Ras transformation. Nature 1995, 374(6521):457-459.
10. Samuel M.S., Lourenço F.C., Olson M.F. K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PLoS One 2011, 6(2):e17143.
11. Heid I., et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 2011, 141(2):719-730. 730.e1-7.
12. Kissil J.L., et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res. 2007, 67(17):8089-8094.
13. Stengel K.R., Zheng Y. Essential role of Cdc42 in Ras-induced transformation revealed by gene targeting. PLoS One 2012, 7(6):e37317.
14. Kumar R., Gururaj A.E., Barnes C.J. p21-activated kinases in cancer. Nat. Rev. Cancer 2006, 6(6):459-471.
15. Ye D.Z., Field J. PAK signaling in cancer. Cell. Logist. 2012, 2(2):105-116.
16. Whale A., et al. Signalling to cancer cell invasion through PAK family kinases. Front. Biosci. 2011, 16:849-864.
17. Kelly M.L., Chernoff J. Mouse models of PAK function. Cell. Logist. 2012, 2(2):84-88.
18. Ong C.C., et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(17):7177-7182.
19. Arias-Romero L.E., et al. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 2010, 29(43):5839-5849.
20. Kimmelman A.C., et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(49):19372-19377.
21. Parsons D.W., et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436(7052):792.
22. Tang Y., et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol. Cell. Biol. 1997, 17(8):4454-4464.
23. Vadlamudi R.K., et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J. Biol. Chem. 2000, 275(46):36238-36244.
24. Liu Y., et al. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol. Cancer Res. 2008, 6(7):1215-1224.
25. Li Q., et al. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia 2008, 10(4):314-329.
26. Chow H.Y., et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 2012, 72(22):5966-5975.
27. Gnad F., et al. Systems-wide analysis of K-Ras, Cdc42 and PAK4 signaling by quantitative phosphoproteomics. Mol. Cell. Proteomics 2013, 12(8):2070-2080.
28. Lei M., et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 2000, 102(3):387-397.
29. Blanck S., et al. The art of filling protein pockets efficiently with octahedral metal complexes. Angew. Chem. Int. Ed. Engl. 2012, 51(21):5244-5246.
30. Wang J., Wu J.W., Wang Z.X. Structural insights into the autoactivation mechanism of p21-activated protein kinase. Structure 2011, 19(12):1752-1761.
31. H. Lu, M. Lei, U. Schulze-Gahmen, PDB ID : crystal structure of the complex between human Pak1-kinase and 3-hydroxystaurosporine, http://dx.doi.org/10.2210/pdb2hy8/pdb.
32. Maksimoska J., et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J. Am. Chem. Soc. 2008, 130(47):15764-15765.
33. Jha R.K., Strauss C.E. 3D structure analysis of PAKs: a clue to the rational design for affinity reagents and blockers. Cell. Logist. 2012, 2(2):69-77.
34. Eswaran J., et al. Crystal structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 2007, 15(2):201-213.
35. Murray B.W., et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(20):9446-9451.
36. Guo C., et al. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. J. Med. Chem. 2012, 55(10):4728-4739.
37. Karaman M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26(1):127-132.
38. Bebbington D., et al. The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg. Med. Chem. Lett. 2009, 19(13):3586-3592.
39. Ioannidis S., et al. Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. J. Med. Chem. 2011, 54(1):262-276.
40. Guo C., et al. Pyrimidine Aminopyrazole Compounds, Potent Kinase Inhibitors 2007, Agouron/Pfizer Inc., La Jolla, CA, WO 2007/023382.
41. I. Aliagas-Martin, et al., Serine/threonine PAK1 inhibitors, F. Hoffmann-La Roche AG, Basel, 2013, WO 2013/026914.
42. Abad-Zapatero C., Metz J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 2005, 10(7):464-469.
43. Bindi S., et al. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity. Bioorg. Med. Chem. 2010, 18(19):7113-7120.
44. Rosen L., et al. Phase 1, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, on oral PAK inhibitor, in patients with advanced solid tumors. Mol. Targets Cancer Ther. 2011, 10(11 Suppl.):A177.
45. Bouzida D., et al. Pyrrolopyrazoles, Potent Kinase Inhibitors 2006, Agouron/Pfizer Inc., La Jolla, CA, WO 2006/072831.
46. Guo C., et al. Discovery of p21-activated kinase inhibitor PF-03758309. Mol. Targets Cancer Ther. 2009, 8(12 Suppl.):p. PR-2.
47. Rosen L., et al. Phase 1, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, on oral PAK inhibitor, in patients with advanced solid tumors. Mol. Targets Cancer Ther. 2011, 10(11 Suppl.):A177.
48. Fancelli D., et al. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. 2005, 48(8):3080-3084.
49. Fancelli D., et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 2006, 49(24):7247-7251.
50. Li H., et al. Identification of novel pyrrolopyrazoles as protein kinase C β II inhibitors. Bioorg. Med. Chem. Lett. 2011, 21(1):584-587.
51. Botrous I., et al. 3-Amino-Pyrrolo [3,4-C]Pyrazole-5(1H, 4H, 6H)Carbaldehyde Derivatives as Inhibitors of Protein Kinase C 2008, Pfizer Inc., WO 2008/125945.
52. Dong L., et al. Carbonylamino Pyrrolopyrazoles, Potent Kinase Inhibitors 2007, Pfizer Products Inc., Groton, CT, WO 2007/072153.
53. Kreis P., Barnier J.V. PAK signalling in neuronal physiology. Cell. Signal. 2009, 21(3):384-393.
54. Say E., et al. A functional requirement for PAK1 binding to the KH(2) domain of the fragile X protein-related FXR1. Mol. Cell 2010, 38(2):236-249.
55. Campbell D., et al. Compounds for Treating Neuropsychiatric Conditions 2010, Afraxis Inc., San Diego, CA, WO 2010/071846.
56. Vollrath B., et al. 8-Ethyl-6-(Aryl)Pyrido[2,3-D]Pyrimidin-7(8H)-Ones for the Treatment of CNS Disorders 2011, Afraxis Inc., San Diego, CA, WO 2011/044535.
57. Campbell D., et al. 6-(Sulfonylaryl)Pyrido[2,3-D]Pyrimidin-7(8H)-Ones for the Treatment of CNS Disorders 2011, Afraxis Inc., La Jolla, CA, WO 2011/156646.
58. Campbell D., et al. 6-(Ethynyl)Pyrido[2,3-D]Pyrimidin-7(8H)-Ones for the Treatment of CNS Disorders 2011, Afraxis Inc., La Jolla, CA, WO 2011/156786.
59. Campbell D., et al. 8-(Heteroarylmethyl)Pyrido[2,3-D]Pyrimidin-7(8H)-Ones for the Treatment of CNS Disorders 2011, Afraxis Inc., La Jolla, CA, WO 2011/156640.
60. Campbell D., et al. 8-(Sulfonylbenzyl)Pyrido[2,3-D]Pyrimidin-7(8H)-Ones for the treatment of CNS Disorders 2011, Afraxis Inc., La Jolla, CA, WO 2011/156780.
61. Campbell D., et al. 8-(2'-Heterocycyl)Pyrido[2.3-D]Pyrimidin-7(8H)-Ones for the Treatment of CNS Disorders 2011, Afraxis Inc., La Jolla, CA, WO 2011/156775.
62. McKew J.C., et al. PAK Inhibitors for the Treatment of Fragile X Syndrome 2013, Afraxis Inc., La Jolla, CA, The United States of America, as Represented by The Secretary, Department of Health and Human Services, Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325 MSC 7660 Bethesda, Maryland 20892-7660 (US): WO 2013/067434.
63. Dolan B.M., et al. Rescue of fragile X syndrome phenotypes in Fmr1KO mice by the small-molecule PAK inhibitor FRAX486. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(14):5671-5676.
64. Campbell D., Duron S.G., Campbell D., Duron S.G. 8-Ethyl-6-(Aryl)Pyrido [2,3-D]Pyrimidin-7(8H) -Ones for the Treatment of Nervous System Disorders and Cancer 2013, Afraxis Inc., WO 2013/043232.
65. Campbell D., Duron S.G. PAK Inhibitors for the Treatment of Cell Proliferative Disorders 2013, Afraxis Inc., La Jolla, CA, WO 2013/067423.
66. Crawford J.J., Hoeflich K.P., Rudolph J. p21-Activated kinase inhibitors: a patent review. Expert. Opin. Ther. Pat. 2012, 22(3):293-310.
67. Xu Y., et al. Synthesis and structure-activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors. Bioorg. Med. Chem. Lett. 2013, 23(14):4072-4075.
68. Metz J.T., et al. Navigating the kinome. Nat. Chem. Biol. 2011, 7(4):200-202.
69. Lin H., et al. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: improved drug-like properties and kinase selectivity from azaindazoles. Bioorg. Med. Chem. Lett. 2010, 20(2):679-683.
70. Heerding D.A., et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J. Med. Chem. 2008, 51(18):5663-5679.
71. Deacon S.W., et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol. 2008, 15(4):322-331.
72. Viaud J., Peterson J.R. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol. Cancer Ther. 2009, 8(9):2559-2565.
73. Wang Z., et al. p21-Activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner. J. Biol. Chem. 2013, 288(27):20093-20099.
74. Genentech, unpublished results.
75. Ma Y., et al. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration. J. Clin. Endocrinol. Metab. 2013, 98(8):E1314-E1322.